Detalles de la búsqueda
1.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 23(2): 279-291, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35033226
2.
Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.
Cancer Immunol Immunother
; 68(8): 1331-1340, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31317218
3.
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.
JCO Precis Oncol
; 6: e2100413, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35797509
4.
Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
Cancer Med
; 10(8): 2627-2635, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33724703
5.
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.
Clin Cancer Res
; 27(9): 2470-2480, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33568343
6.
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.
Clin Cancer Res
; 27(17): 4940, 2021 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34470811
Resultados
1 -
6
de 6
1
Próxima >
>>